113. Muscular dystrophy
567 clinical trials,   442 drugs   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways

Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-009871-36-DE
(EUCTR)
06/08/2009Study within children with Duchenne Muscular DystrophyEffect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy - DMD-Kardio Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]Trade Name: EnalHexal®, 5 mg
INN or Proposed INN: ENALAPRIL
Trade Name: EnaHexal®, 10mg
INN or Proposed INN: ENALAPRIL
Trade Name: MetoHEXAL® Succ ® 23,75 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE
Trade Name: MetoHEXAL® Succ ® 47,5 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE
Trade Name: MetoHEXAL® Succ ® 95 mg Retardtabletten
INN or Proposed INN: METOPROLOL SUCCINATE
Friedrich- Alexander- Universität Erlangen NürnbergNULLNot RecruitingFemale: no
Male: yes
Germany